Response to: 'Tocilizumab in patients with adult-onset Still's disease refractory to glucocorticoid treatment' by Lee

Affiliations

¹ Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan ykaneko@z6.keio.jp.
² Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
³ Division of Rheumatology, Department of Internal Medicine, Toho University Ohashi Medical Center, Tokyo, Japan.
⁴ Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan.
⁵ Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
⁶ Department of Rheumatology and Clinical Immunology, Kyoto University, Kyoto, Japan.
⁷ Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka, Japan.
⁸ The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
⁹ Department of Preventive Medicine and Public Health, Biostatistics at Clinical and Translational Research Center, Keio University School of Medicine, Tokyo, Japan.

Comment

Yuko Kaneko et al. Ann Rheum Dis. 2019 Dec.

. 2019 Dec;78(12):e134.

doi: 10.1136/annrheumdis-2018-214653. Epub 2018 Nov 10.

¹ Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan ykaneko@z6.keio.jp.
² Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
³ Division of Rheumatology, Department of Internal Medicine, Toho University Ohashi Medical Center, Tokyo, Japan.
⁴ Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan.
⁵ Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
⁶ Department of Rheumatology and Clinical Immunology, Kyoto University, Kyoto, Japan.
⁷ Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka, Japan.
⁸ The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
⁹ Department of Preventive Medicine and Public Health, Biostatistics at Clinical and Translational Research Center, Keio University School of Medicine, Tokyo, Japan.

No abstract available

Keywords: adult onset still's disease; cytokines; treatment.

Conflict of interest statement

Competing interests: None declared.

Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial.
Kaneko Y, Kameda H, Ikeda K, Ishii T, Murakami K, Takamatsu H, Tanaka Y, Abe T, Takeuchi T. Kaneko Y, et al. Ann Rheum Dis. 2018 Dec;77(12):1720-1729. doi: 10.1136/annrheumdis-2018-213920. Epub 2018 Oct 2. Ann Rheum Dis. 2018. PMID: 30279267 Clinical Trial.
Tocilizumab in patients with adult-onset Still's disease refractory to glucocorticoid treatment.
Lee YH. Lee YH. Ann Rheum Dis. 2019 Dec;78(12):e133. doi: 10.1136/annrheumdis-2018-214635. Epub 2018 Nov 2. Ann Rheum Dis. 2019. PMID: 30389689 No abstract available.